ImmunoGen Inc (IMGN) Stock Price & Overview
NASDAQ:IMGN • US45253H1014
Current stock price
The current stock price of IMGN is 31.23 USD. Today IMGN is down by 0%. In the past month the price increased by 5.15%. In the past year, price increased by 617.93%.
IMGN Key Statistics
- Market Cap
- 8.724B
- P/E
- N/A
- Fwd P/E
- 81.49
- EPS (TTM)
- -0.31
- Dividend Yield
- N/A
IMGN Stock Performance
IMGN Stock Chart
IMGN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to IMGN. When comparing the yearly performance of all stocks, IMGN is one of the better performing stocks in the market, outperforming 99.75% of all stocks.
IMGN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMGN. While IMGN seems to be doing ok healthwise, there are quite some concerns on its profitability.
IMGN Earnings
IMGN Forecast & Estimates
19 analysts have analysed IMGN and the average price target is 31.69 USD. This implies a price increase of 1.46% is expected in the next year compared to the current price of 31.23.
For the next year, analysts expect an EPS growth of 108.78% and a revenue growth 344.16% for IMGN
IMGN Groups
Sector & Classification
IMGN Financial Highlights
Over the last trailing twelve months IMGN reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS increased by 62.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.94% | ||
| ROE | -13.09% | ||
| Debt/Equity | 0.16 |
IMGN Ownership
IMGN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.11 | 373.296B | ||
| AMGN | AMGEN INC | 15.28 | 190.378B | ||
| GILD | GILEAD SCIENCES INC | 15.19 | 169.926B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.34 | 115.264B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.78 | 80.002B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.53 | 43.521B | ||
| INSM | INSMED INC | N/A | 31.815B | ||
| BIIB | BIOGEN INC | 11.43 | 28.04B | ||
| NTRA | NATERA INC | N/A | 27.8B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.5 | 23.341B | ||
| MRNA | MODERNA INC | N/A | 21.157B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.471B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IMGN
Company Profile
ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. The company is headquartered in Waltham, Massachusetts and currently employs 277 full-time employees. The firm is focused on developing and commercializing of antibody- drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its ELAHERE (Mirvetuximab Soravtansine) is a first-in-class ADC targeting folate receptor alpha (FRa), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Its Pivekimab sunirine (PVEK), is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. The firm is advancing PVEK in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).
Company Info
IPO: 1989-11-17
ImmunoGen Inc
830 Winter Street
Waltham MASSACHUSETTS 02451 US
CEO: Mark J. Enyedy
Employees: 277
Phone: 17818950600
ImmunoGen Inc / IMGN FAQ
Can you describe the business of ImmunoGen Inc?
ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. The company is headquartered in Waltham, Massachusetts and currently employs 277 full-time employees. The firm is focused on developing and commercializing of antibody- drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its ELAHERE (Mirvetuximab Soravtansine) is a first-in-class ADC targeting folate receptor alpha (FRa), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Its Pivekimab sunirine (PVEK), is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. The firm is advancing PVEK in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).
What is the stock price of ImmunoGen Inc today?
The current stock price of IMGN is 31.23 USD.
Does IMGN stock pay dividends?
IMGN does not pay a dividend.
How is the ChartMill rating for ImmunoGen Inc?
IMGN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of ImmunoGen Inc (IMGN) based on its PE ratio?
ImmunoGen Inc (IMGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.31).
Can you provide the market cap for ImmunoGen Inc?
ImmunoGen Inc (IMGN) has a market capitalization of 8.72B USD. This makes IMGN a Mid Cap stock.